Escherichia coli is one of the most prevalent gram-negative bacteria that cause several intestinal and other organ infections, such as septicemia, pneumonia, neonatal meningitis, and urinary tract infections (UTIs) (
1,
2). Recently,
E. coli has become resistant to many antibiotics. In addition to antibiotic resistance, some studies have reported a reduction in the effects of disinfectant compounds on
E. coli, which can be an important health problem (
3). Reduced effectiveness of biocides may result from consecutive contact of bacteria with biocides (
4). Antimicrobial biocides have various effects on microorganisms, such as causing cytoplasmic membrane damage, nucleic acid destruction, or ribosome denaturation (
5). In bacteria, the reduction of the effect of biocides can result from intrinsic factors like the outer membrane of gram-negative bacteria, arabinogalactan in the cell wall of mycobacteria, biofilm formation, changes in enzyme structure, expression of stress response genes, efflux pump activity, mutation, or acquisition of genetic elements carrying tolerance genes for biocides, as well as the acquisition or upregulation of efflux pump genes located on plasmids, T3 transposons, composite transposons, or conjugative transposons (
6-
8).
Hospital-acquired
E. coli isolates are resistant to antimicrobial biocides in two ways: The first type of resistance is intrinsic, involving control of the influence of compounds into the cell, and the second involves acquiring an extrinsic gene that reduces the influence of biocides into the cell, reduces permeability, or enhances efflux pump activity (
5).
mdfA,
emrE,
qacA/B,
qacED1,
qacE,
qacG,
qacH, and
qacJ are examples of efflux pump genes found in the plasmid or chromosomal genome of some bacteria, such as Staphylococci and Enterobacteriaceae (
9).